Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983617 | 0.78 | PLA2G4B (0.57) | SRD5A2NR1H4RARBNPC1RAB9A | |
| SCHEMBL16519363 | 0.77 | NQO1 (0.46) | NPC1RAB9A | |
| SCHEMBL1602489 | 0.75 | RAB9A (0.47) | PPARANPC1RAB9APPARDPPARG | |
| SCHEMBL1465494 | 0.74 | KMT2A (0.57) | PPARANR1H4FFAR1 | |
| SCHEMBL14984814 | 0.73 | LTA4H (0.50) | — | |
| SCHEMBL9856614 | 0.73 | SLC6A3 (0.53) | NPC1RAB9AALPL | |
| SCHEMBL7442362 | 0.73 | PLA2G4B (0.49) | PPARAFFAR1PLA2G4B | |
| SCHEMBL16669733 | 0.72 | PPARA (0.39) | PPARAFFAR1PLA2G4BPPARDPPARG | |
| SCHEMBL103360 | 0.72 | MAPT (0.65) | RAB9A | |
| SCHEMBL17400969 | 0.72 | NQO1 (0.61) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758510-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160332997-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-11-17 | — | — | US | disclosed |
| US-20150119441-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332997-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PPARA 761/4885SRD5A2 3434/4885NR1H4 101/4885 |
| US-20150119441-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | PPARA 761/4885SRD5A2 3434/4885NR1H4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.